Who are Megestrol Acetate and olanzapine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/megestrol-acetate-and-olanzapine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Megestrol Acetate and olanzapine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Megestrol Acetate and olanzapine (Megestrol Acetate and olanzapine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Progestin + atypical antipsychotic combination. Area: Oncology / Palliative Care / Cachexia.

phase 3 Progestin + atypical antipsychotic combination Hypothalamic appetite centers (megestrol); dopamine D2 and serotonin 5-HT2A receptors (olanzapine) Oncology / Palliative Care / Cachexia Small molecule Live · refreshed every 30 min

Target snapshot

Megestrol Acetate and olanzapine (Megestrol Acetate and olanzapine) — Qingdao Central Hospital. This combination uses megestrol acetate (a progestin) to stimulate appetite and promote weight gain, while olanzapine (an atypical antipsychotic) provides additional appetite stimulation and may address underlying psychiatric or behavioral symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Megestrol Acetate and olanzapine TARGET	Megestrol Acetate and olanzapine	Qingdao Central Hospital	phase 3	Progestin + atypical antipsychotic combination	Hypothalamic appetite centers (megestrol); dopamine D2 and serotonin 5-HT2A receptors (olanzapine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Progestin + atypical antipsychotic combination class)

Qingdao Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Megestrol Acetate and olanzapine — Competitive Intelligence Brief. https://druglandscape.com/ci/megestrol-acetate-and-olanzapine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab